August 6, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter ended June 30, 2026

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 1:26 P.M. (IST) and ended at 1:43 P.M.), the Unaudited Financial Results for the quarter ended June 30, 2026 were approved.

We are enclosing herewith the following:

a. Unaudited Financial Results for the quarter ended June 30, 2026;
b. Limited Review Report, in respect of the Unaudited Financial Results for the quarter ended June 30, 2026, as furnished by the Statutory Auditors of the Company;

Kindly take the same on record.

Thanking you.

For **Procter & Gamble Health Limited**

Flavia Peter Machado
Digitally signed by Flavia Peter Machado
Date: 2026.08.06 13:50:25 +05'30'

Flavia Machado
Authorized Signatory

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors
Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

HARIBHAKTI & CO. LLP ★ MUMBAI ★ CHARTERED ACCOUNTANTS

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048

HARIBHAKTI & CO. LLP
MUMBAI
CHARTERED ACCOUNTANTS

Sumant Sakhardande
Partner
Membership No.: 034828
UDIN: 26034828ZDFPLL6389
Place: Mumbai
Date: August 06, 2026

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(₹ in lakhs)

Sr. No.	Particulars	(1) Three months ended 30th June 2026 (Unaudited)	(2) Preceding Three months ended 31st March 2026 (Audited) (Refer note 4 below)	(3) Corresponding Three months ended 30th June 2025 (Unaudited)	(4) Previous Year ended 31st March 2026 (Audited)
1.	**Revenue from Operations**	36 371	37 045	33 874	140 797
2.	**Other Income**	388	400	403	1 734
3.	**Total Income (1+2)**	36 759	37 445	34 277	142 531
	Expenses				
	a) Cost of materials consumed	8 031	8 519	5 954	30 733
	b) Purchases of stock-in-trade (Traded goods)	2 456	2 231	2 431	7 058
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(865)	(1 463)	1 014	(1 283)
	d) Employee benefits expenses	6 039	5 086	5 601	22 256
	e) Depreciation and amortisation expenses	602	617	544	2 359
	f) Finance costs	14	21	12	55
	g) Other expenses	10 750	9 113	9 840	36 367
4.	**Total expenses (4)**	27 027	24 124	25 396	97 545
5.	**Profit before exceptional items and tax (3-4)**	9 732	13 321	8 881	44 986
6.	Add: Exceptional item (refer note 7)	3 180	-	-	-
7.	**Profit before tax (5+6)**	12 912	13 321	8 881	44 986
8.	**Tax expenses**				
	a) Current Tax	3 103	2 808	2 294	11 082
	b) Deferred Tax Charge / (Credit)	194	650	(31)	446
	c)Adjustment of tax relating to earlier periods	-	403	-	767
	Total tax expenses	3 297	3 861	2 263	12 295
9.	**Net Profit for the period / year (7-8)**	9 615	9 460	6 618	32 691
10.	**Other Comprehensive Income**				
	Items that will not be reclassified to profit or loss				
	i. Re-measurement gains / (losses) on defined benefit plans	41	(392)	(87)	(38)
	ii.Income tax effect on above	(10)	99	22	10
	Other Comprehensive Income, net of tax	31	(293)	(65)	(28)
11.	**Total Comprehensive Income for the period / year (9+10)**	9 646	9 167	6 553	32 663
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660
13.	Other equity	-	-	-	50 795
14.	**Earnings per equity share (of ₹ 10/- each)**				
	*(not annualised)				
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 38.77	* 56.99	* 39.87	196.94
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 57.92	* 56.99	* 39.87	196.94

PROCTER & GAMBLE HEALTH LIMITED MUMBAI

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 6, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company.These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and expressed "Unmodified" conclusion

2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable

3. The Company does not have a subsidiary, an associate or a joint venture as at 30 June, 2026.

4. The figures for the preceeding three months ended March 31, 2026, are the balancing figures between the audited figures in respect of the year ended March 31, 2026 and the published unaudited year to date figures upto the third quarter ended December 31, 2025.

5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.

6. The unaudited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

7. During the quarter ended June 30, 2026, the Company sold its office premises property located at Worli for ₹ 3 334 Lakhs. The carrying amount of the property as at date of sale was ₹ 154 Lakhs. The gain arising from the sale amounting to ₹ 3 180 Lakhs has been disclosed as an exceptional item for the quarter ended June 30, 2026.

8. Previous year's / quarter's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's /quarter's classification

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

PROCTER & GAMBLE HEALTH LIMITED ★ MUMBAI

Milind Thatte
Managing Director

Place : Mumbai
Date : August 6, 2026